The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.

Butler, J., Fonarow, G., Zile, M., Lam, C., Roessig, L., Schelbert, E., et al. (2014). Developing Therapies for Heart Failure With Preserved Ejection Fraction Current State and Future Directions. JACC. HEART FAILURE, 2(2), 97-112 [10.1016/j.jchf.2013.10.006].

Developing Therapies for Heart Failure With Preserved Ejection Fraction Current State and Future Directions

Senni M;
2014

Abstract

The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.
Articolo in rivista - Articolo scientifico
Epidemiology; Heart failure; Preserved ejection fraction; Prognosis; Treatment;
English
97
112
16
Butler, J., Fonarow, G., Zile, M., Lam, C., Roessig, L., Schelbert, E., et al. (2014). Developing Therapies for Heart Failure With Preserved Ejection Fraction Current State and Future Directions. JACC. HEART FAILURE, 2(2), 97-112 [10.1016/j.jchf.2013.10.006].
Butler, J; Fonarow, G; Zile, M; Lam, C; Roessig, L; Schelbert, E; Shah, S; Ahmed, A; Bonow, R; Cleland, J; Cody, R; Chioncel, O; Collins, S; Dunnmon, P; Filippatos, G; Lefkowitz, M; Marti, C; Mcmurray, J; Misselwitz, F; Nodari, S; O'Connor, C; Pfeffer, M; Pieske, B; Pitt, B; Rosano, G; Sabbah, H; Senni, M; Solomon, S; Stockbridge, N; Teerlink, J; Georgiopoulou, V; Gheorghiade, M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/372085
Citazioni
  • Scopus 246
  • ???jsp.display-item.citation.isi??? 236
Social impact